Literature DB >> 2920215

Characterization of the potentiation effect of activin on human erythroid colony formation in vitro.

J Yu1, L Shao, J Vaughan, W Vale, A L Yu.   

Abstract

Activin, also named FSH-releasing protein, was previously shown to induce hemoglobin accumulation in K562 cells and potentiate the proliferation and differentiation of CFU-E in human bone marrow cultures. Present studies indicate that the potentiation effect of activin is lineage specific. In addition to CFU-E, activin caused an increase in the colony formation of BFU-E from either bone marrow or peripheral blood. It had little effect on the colony formation of CFU-GM and the mixed colonies from CFU-GEMM. In serum-depleted culture, the effect of activin was shown to be dose-dependent with doses effective at picomolar concentrations. The potentiation effect of activin was exerted indirectly through mediation of both monocytes and T lymphocytes. Activin was also found to increase specifically the proportion of DNA-synthesizing erythroid progenitors from both bone marrow and peripheral blood. It had little effect on DNA synthesis in CFU-GM and in mitogen-stimulated lymphocytes. Addition of the monocytes or T lymphocytes to their respective depleted subpopulations of mononuclear cells reconstituted the enhancing effect of activin on the colony formation and DNA synthesis of erythroid progenitors. These results strongly suggest a specific role of activin in potentiating the proliferation and differentiation of erythroid progenitors in vitro.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2920215

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Biological inducers of haemopoietic differentiation.

Authors:  S Eridani; E Abood
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

2.  Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid.

Authors:  J Yu; L E Shao; N L Frigon; J Lofgren; R Schwall
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

3.  Overexpression of activin A in stage IV colorectal cancer.

Authors:  S Wildi; J Kleeff; H Maruyama; C A Maurer; M W Büchler; M Korc
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

4.  EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.

Authors:  Ayse Batova; Howard Cottam; John Yu; Mitchell B Diccianni; Carlos J Carrera; Alice L Yu
Journal:  Blood       Date:  2005-10-18       Impact factor: 22.113

Review 5.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923

6.  Two-day-treatment of Activin-A leads to transient change in SV-HFO osteoblast gene expression and reduction in matrix mineralization.

Authors:  Marta Baroncelli; Ksenija Drabek; Marco Eijken; Bram C J van der Eerden; Jeroen van de Peppel; Johannes P T M van Leeuwen
Journal:  J Cell Physiol       Date:  2019-10-30       Impact factor: 6.384

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.